NCT00964327View on ClinicalTrials.gov

TMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) Strains

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 31, 2001

Primary Completion Date

October 31, 2003

Study Completion Date

October 31, 2003

Conditions
HIV Infections
Interventions
DRUG

TMC114

All Listed Sponsors
lead

Tibotec Pharmaceuticals, Ireland

INDUSTRY

NCT00964327 - TMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) Strains | Biotech Hunter | Biotech Hunter